0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD4

CD4

Brief Information

Name:T-cell surface antigen CD4
Target Synonym:CD4mut,CD4 Antigens,T-cell surface antigen T4/Leu-3,T-cell surface glycoprotein CD4,CD4,CD4 Molecule,CD4 Antigen (P55),CD4 Receptor,CD4 Antigen
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD4-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CD4 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD4, His Tag (Cat. No. CD4-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CD4-HF2H7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of CD4-CAR-293 cells were stained with 100 μL of 0.3 μg/mL of FITC-Labeled Human CD4, His Tag (Cat. No. CD4-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD4-HF255-ELISA
FITC-Labeled Human CD4, Fc TagFITC-Labeled Human CD4, Fc Tag (Cat. No. CD4-HF255) ELISA bioactivity

Immobilized Ibalizumab (Human IgG4) at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD4, Fc Tag (Cat. No. CD4-HF255) with a linear range of 20-313 ng/mL (QC tested).

CD4-H82E8-MALS-HPLC
Biotinylated Human CD4, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human CD4, His,Avitag (Cat. No. CD4-H82E8) was more than 90% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human CD4, His,AvitagBiotinylated Human CD4, His,Avitag (Cat. No. CD4-H82E8) ELISA bioactivity

Immobilized Ibalizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Human CD4, His,Avitag (Cat. No. CD4-H82E8) with a linear range of 0.2-3 ng/mL (QC tested).

Synonym Name

CD4,CD4mut,LEU3

Background

Cluster of Differentiation 4 (CD4) is also known as T-cell surface antigen T4/Leu-3 (LEU-3) and CD4mut, is a single-pass type I  membrane glycoprotein,and is a member of the immunoglobulin superfamily. CD4 expressed on the surface of T helper cells, monocytes, macrophages, and dendritic cells. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell: D1 and D3 resemble immunoglobulin variable (IgV) domains. D2 and D4 resemble immunoglobulin constant (IgC) domains. CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the tyrosine kinase lck, which is essential for activating many molecules involved in the signaling cascade of an activated T cell. CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain. The extracellular domain adopts an immunoglobulin-like beta-sandwich with seven strands in 2 beta sheets, in a Greek key topology. CD4 has also been shown to interact with SPG21, Lck and Protein unc-119 homolog. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ibalizumab Hu5A8; TMB-355; TNX-355; 5AB Approved Biogen Inc Trogarzo EU HIV Infections Theratechnologies Europe Ltd 2018-03-06 HIV Infections Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IT-1208 (Kyowa Hakko Kirin) IT-1208 Phase 1 Clinical Kyowa Hakko Kirin Neoplasms Details
LCAR-T2C CAR-T cell therapy (Nanjing Medical University) Phase 1 Clinical The First Affiliated Hospital With Nanjing Medical University Lymphoma, T-Cell Details
T-allo-10 T-allo-10 Phase 1 Clinical Stanford University Graft vs Host Disease Details
ITV 1(Nonindustrial source) ITV-1 Phase 3 Clinical Synexa Life Sciences, Immunotech Laboratories, Nonindustrial Source HIV Infections Details
CD4-directed chimeric antigen receptor engineered T-cells (Stony Brook University) CD4CAR Phase 1 Clinical Stony Brook University School Of Medicine, Icell Gene Therapeutics, University Of Louisville Leukemia; Lymphoma, T-Cell Details
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) CAR-C34ZFN Phase 1 Clinical University Of Pennsylvania HIV Infections Details
VRC-07-523 VRC-07-523; VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB Phase 1 Clinical National Institutes Of Health HIV Infections Details
MVA-EL MVA-EBNA1/LMP2 Phase 2 Clinical Chinese University Of Hong Kong (Cuhk), Cancer Research Uk Nasopharyngeal Neoplasms Details
Tregalizumab hB-F5; BT-061 Phase 2 Clinical Biotest Pharma Gmbh Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma Details
Anti-CD3 anti-CD20 bispecific antibody (Genmab) GEN-3013 Phase 2 Clinical Genmab Hematologic Neoplasms Details
CALRLong36 peptide (Herlev Hospital) Phase 1 Clinical Herlev Hospital Myeloproliferative Disorders Details
CD4 CAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Lymphoma, T-Cell Details
GEN-009 GEN-009 Phase 2 Clinical Genocea Biosciences Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
Anti-CD4 CAR-T (Legend) Phase 1 Clinical Lymphoma, T-Cell Details
VRC-HIVAAV070-00-GT AAV8-VRC07 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
VRC-01-LS VRC-01-LS; VRC-HIVMAB-080-00-AB Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
BG-8962 BG-8962 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
VRC-HIVMAB091-00-AB N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
Mosedipimod EC-18 Phase 2 Clinical Enzychem Lifesciences Neutropenia; Coronavirus Disease 2019 (COVID-19); Stomatitis; Febrile Neutropenia Details
TMB-365 TMB-365 Phase 1 Clinical Taimed Biologics Inc HIV Infections Details
LB-1901 LB-1901; LB1901 Phase 1 Clinical Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous Details
RB-0003 RB-0003; BNT-111 Phase 2 Clinical Biontech Se, Tron Melanoma Details
UB-421 dB4; UB-421; mAb-B4 Phase 3 Clinical United Biomedical Inc HIV Infections Details

This web search service is supported by Google Inc.

totop